Literature DB >> 10548519

TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF.

R J Sells Galvin1, C L Gatlin, J W Horn, T R Fuson.   

Abstract

TGF-beta has been shown to inhibit and stimulate osteoclastogenesis. The purpose of this study was to evaluate the effects of TGF-beta in hematopoietic cell cultures stimulated with RANKL and M-CSF. In cocultures of hematopoietic cells and BALC cells (a calvarial-derived cell line), TGF-beta inhibited tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cell formation. In contrast, TGF-beta enhanced TRAP-positive multinucleated cell formation up to 10-fold in hematopoietic cell cultures containing few osteoblastic/stromal cells. Likewise, TGF-beta increased the number of calcitonin receptor (CTR)-positive multinucleated and mononucleated cells in a concentration-dependent manner. An increase in cell size and multinuclearity was also observed in the presence of TGF-beta. The stimulatory effects of TGF-beta were dependent on the presence of M-CSF and RANKL. When differentiated on bovine cortical bone slices, these cells formed resorption lacunae. These results suggest that TGF-beta has a direct stimulatory effect on osteoclastogenesis in hematopoietic cells treated with RANKL and M-CSF. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548519     DOI: 10.1006/bbrc.1999.1632

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

Review 1.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  The roles of vascular endothelial growth factor in bone repair and regeneration.

Authors:  Kai Hu; Bjorn R Olsen
Journal:  Bone       Date:  2016-06-25       Impact factor: 4.398

3.  TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Authors:  Anne Gingery; Elizabeth W Bradley; Larry Pederson; Ming Ruan; Nikki J Horwood; Merry Jo Oursler
Journal:  Exp Cell Res       Date:  2008-06-13       Impact factor: 3.905

4.  Inhibition of osteoclastogenesis by stem cell-derived extracellular matrix through modulation of intracellular reactive oxygen species.

Authors:  Mao Li; Xi Chen; Jinku Yan; Long Zhou; Yifan Wang; Fan He; Jun Lin; Caihong Zhu; Guoqing Pan; Jia Yu; Ming Pei; Huilin Yang; Tao Liu
Journal:  Acta Biomater       Date:  2018-03-08       Impact factor: 8.947

5.  Injectable RANKL sustained release formulations to accelerate orthodontic tooth movement.

Authors:  Joy H Chang; Po-Jung Chen; Michael R Arul; Eliane H Dutra; Ravindra Nanda; Sangamesh G Kumbar; Sumit Yadav
Journal:  Eur J Orthod       Date:  2020-06-23       Impact factor: 3.075

6.  TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.

Authors:  Jeroen T Buijs; Keith R Stayrook; Theresa A Guise
Journal:  Cancer Microenviron       Date:  2011-07-12

7.  PAK1 is a novel MEK-independent raf target controlling expression of the IAP survivin in M-CSF-mediated osteoclast survival.

Authors:  Elizabeth W Bradley; Ming M Ruan; Merry J Oursler
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

8.  A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss.

Authors:  Hisako Hikiji; Satoshi Ishii; Takehiko Yokomizo; Tsuyoshi Takato; Takao Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-24       Impact factor: 11.205

9.  Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival.

Authors:  Elizabeth W Bradley; Ming M Ruan; Anne Vrable; Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

10.  Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.

Authors:  Mary Karst; Genevieve Gorny; Rachelle J Sells Galvin; Merry Jo Oursler
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.